Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
The treatment of neuroblastoma has produced remarkable results with intensive combination chemotherapy. The authors attempted to reduce the duration of treatment in patients with intermediate-risk disease while maintaining a 3-year overall survival rate of more than 90%. Neuroblastoma is the most co...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2010-09, Vol.363 (14), p.1313-1323 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1323 |
|---|---|
| container_issue | 14 |
| container_start_page | 1313 |
| container_title | The New England journal of medicine |
| container_volume | 363 |
| creator | Baker, David L Schmidt, Mary L Cohn, Susan L Maris, John M London, Wendy B Buxton, Allen Stram, Daniel Castleberry, Robert P Shimada, Hiroyuki Sandler, Anthony Shamberger, Robert C Look, A. Thomas Reynolds, C. Patrick Seeger, Robert C Matthay, Katherine K |
| description | The treatment of neuroblastoma has produced remarkable results with intensive combination chemotherapy. The authors attempted to reduce the duration of treatment in patients with intermediate-risk disease while maintaining a 3-year overall survival rate of more than 90%.
Neuroblastoma is the most common extracranial solid tumor in childhood, accounting for 50% of neoplasms diagnosed in the first year of life.
1
This disease has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending on the biologic features of the tumor.
2
–
6
Identification of risk groups on the basis of clinical and molecular prognostic variables has allowed tailoring of therapy to improve outcomes and minimize the risk of deleterious consequences of therapy.
7
–
14
In 1998, the Children's Oncology Group (COG) established a system of risk stratification for neuroblastoma that was based on clinical data (the patient's . . . |
| doi_str_mv | 10.1056/NEJMoa1001527 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_755967799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2151593791</sourcerecordid><originalsourceid>FETCH-LOGICAL-m267t-d2d621658e1f978f703475ecdce1bdd4233f90584c90263e33805500849108cd3</originalsourceid><addsrcrecordid>eNpVkM1PAjEQxRujEUSPXs3GxOPq9GvbHg0BxSAkRM9N2c4GkFLs7h74710DHpzLO8wvb-Y9Qm4pPFKQxdNs9PYeHQWgkqkz0qeS81wIKM5JH4DpXCjDe-SqrjfQDRXmkvQYaGW0hj4Zz9umjAEzVzWYsgX6tkSfDVcYYrPC5PaHrIopm-y6dUC_dg3mi3X9lc2wTXG5dXUTg7smF5Xb1nhz0gH5HI8-hq_5dP4yGT5P88AK1eSe-YLRQmqklVG6UsCFklj6EunSe8E4rwxILUoDrODIuQYpAbQwFHTp-YDcH333KX63WDd2E9u0605aJaUplDKmg-5OULvsXrb7tA4uHexf6g54OAIh1HaHm2Ap2N827b82-Q__TmMS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755967799</pqid></control><display><type>article</type><title>Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Baker, David L ; Schmidt, Mary L ; Cohn, Susan L ; Maris, John M ; London, Wendy B ; Buxton, Allen ; Stram, Daniel ; Castleberry, Robert P ; Shimada, Hiroyuki ; Sandler, Anthony ; Shamberger, Robert C ; Look, A. Thomas ; Reynolds, C. Patrick ; Seeger, Robert C ; Matthay, Katherine K</creator><creatorcontrib>Baker, David L ; Schmidt, Mary L ; Cohn, Susan L ; Maris, John M ; London, Wendy B ; Buxton, Allen ; Stram, Daniel ; Castleberry, Robert P ; Shimada, Hiroyuki ; Sandler, Anthony ; Shamberger, Robert C ; Look, A. Thomas ; Reynolds, C. Patrick ; Seeger, Robert C ; Matthay, Katherine K ; Children’s Oncology Group</creatorcontrib><description>The treatment of neuroblastoma has produced remarkable results with intensive combination chemotherapy. The authors attempted to reduce the duration of treatment in patients with intermediate-risk disease while maintaining a 3-year overall survival rate of more than 90%.
Neuroblastoma is the most common extracranial solid tumor in childhood, accounting for 50% of neoplasms diagnosed in the first year of life.
1
This disease has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending on the biologic features of the tumor.
2
–
6
Identification of risk groups on the basis of clinical and molecular prognostic variables has allowed tailoring of therapy to improve outcomes and minimize the risk of deleterious consequences of therapy.
7
–
14
In 1998, the Children's Oncology Group (COG) established a system of risk stratification for neuroblastoma that was based on clinical data (the patient's . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1001527</identifier><identifier>PMID: 20879880</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject><![CDATA[Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Carboplatin - administration & dosage ; Chemotherapy ; Child ; Child, Preschool ; Children & youth ; Cyclophosphamide - administration & dosage ; Deoxyribonucleic acid ; DNA ; Doxorubicin - administration & dosage ; Etoposide - administration & dosage ; Humans ; Infant ; Intention to Treat Analysis ; Medical research ; Neoplasm Staging ; Neuroblastoma - drug therapy ; Neuroblastoma - mortality ; Neuroblastoma - pathology ; Prospective Studies ; Survival Analysis ; Treatment Outcome]]></subject><ispartof>The New England journal of medicine, 2010-09, Vol.363 (14), p.1313-1323</ispartof><rights>Copyright © 2010 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1001527$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1001527$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20879880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baker, David L</creatorcontrib><creatorcontrib>Schmidt, Mary L</creatorcontrib><creatorcontrib>Cohn, Susan L</creatorcontrib><creatorcontrib>Maris, John M</creatorcontrib><creatorcontrib>London, Wendy B</creatorcontrib><creatorcontrib>Buxton, Allen</creatorcontrib><creatorcontrib>Stram, Daniel</creatorcontrib><creatorcontrib>Castleberry, Robert P</creatorcontrib><creatorcontrib>Shimada, Hiroyuki</creatorcontrib><creatorcontrib>Sandler, Anthony</creatorcontrib><creatorcontrib>Shamberger, Robert C</creatorcontrib><creatorcontrib>Look, A. Thomas</creatorcontrib><creatorcontrib>Reynolds, C. Patrick</creatorcontrib><creatorcontrib>Seeger, Robert C</creatorcontrib><creatorcontrib>Matthay, Katherine K</creatorcontrib><creatorcontrib>Children’s Oncology Group</creatorcontrib><title>Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The treatment of neuroblastoma has produced remarkable results with intensive combination chemotherapy. The authors attempted to reduce the duration of treatment in patients with intermediate-risk disease while maintaining a 3-year overall survival rate of more than 90%.
Neuroblastoma is the most common extracranial solid tumor in childhood, accounting for 50% of neoplasms diagnosed in the first year of life.
1
This disease has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending on the biologic features of the tumor.
2
–
6
Identification of risk groups on the basis of clinical and molecular prognostic variables has allowed tailoring of therapy to improve outcomes and minimize the risk of deleterious consequences of therapy.
7
–
14
In 1998, the Children's Oncology Group (COG) established a system of risk stratification for neuroblastoma that was based on clinical data (the patient's . . .</description><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Carboplatin - administration & dosage</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children & youth</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Doxorubicin - administration & dosage</subject><subject>Etoposide - administration & dosage</subject><subject>Humans</subject><subject>Infant</subject><subject>Intention to Treat Analysis</subject><subject>Medical research</subject><subject>Neoplasm Staging</subject><subject>Neuroblastoma - drug therapy</subject><subject>Neuroblastoma - mortality</subject><subject>Neuroblastoma - pathology</subject><subject>Prospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkM1PAjEQxRujEUSPXs3GxOPq9GvbHg0BxSAkRM9N2c4GkFLs7h74710DHpzLO8wvb-Y9Qm4pPFKQxdNs9PYeHQWgkqkz0qeS81wIKM5JH4DpXCjDe-SqrjfQDRXmkvQYaGW0hj4Zz9umjAEzVzWYsgX6tkSfDVcYYrPC5PaHrIopm-y6dUC_dg3mi3X9lc2wTXG5dXUTg7smF5Xb1nhz0gH5HI8-hq_5dP4yGT5P88AK1eSe-YLRQmqklVG6UsCFklj6EunSe8E4rwxILUoDrODIuQYpAbQwFHTp-YDcH333KX63WDd2E9u0605aJaUplDKmg-5OULvsXrb7tA4uHexf6g54OAIh1HaHm2Ap2N827b82-Q__TmMS</recordid><startdate>20100930</startdate><enddate>20100930</enddate><creator>Baker, David L</creator><creator>Schmidt, Mary L</creator><creator>Cohn, Susan L</creator><creator>Maris, John M</creator><creator>London, Wendy B</creator><creator>Buxton, Allen</creator><creator>Stram, Daniel</creator><creator>Castleberry, Robert P</creator><creator>Shimada, Hiroyuki</creator><creator>Sandler, Anthony</creator><creator>Shamberger, Robert C</creator><creator>Look, A. Thomas</creator><creator>Reynolds, C. Patrick</creator><creator>Seeger, Robert C</creator><creator>Matthay, Katherine K</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20100930</creationdate><title>Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma</title><author>Baker, David L ; Schmidt, Mary L ; Cohn, Susan L ; Maris, John M ; London, Wendy B ; Buxton, Allen ; Stram, Daniel ; Castleberry, Robert P ; Shimada, Hiroyuki ; Sandler, Anthony ; Shamberger, Robert C ; Look, A. Thomas ; Reynolds, C. Patrick ; Seeger, Robert C ; Matthay, Katherine K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-m267t-d2d621658e1f978f703475ecdce1bdd4233f90584c90263e33805500849108cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Carboplatin - administration & dosage</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children & youth</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Doxorubicin - administration & dosage</topic><topic>Etoposide - administration & dosage</topic><topic>Humans</topic><topic>Infant</topic><topic>Intention to Treat Analysis</topic><topic>Medical research</topic><topic>Neoplasm Staging</topic><topic>Neuroblastoma - drug therapy</topic><topic>Neuroblastoma - mortality</topic><topic>Neuroblastoma - pathology</topic><topic>Prospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baker, David L</creatorcontrib><creatorcontrib>Schmidt, Mary L</creatorcontrib><creatorcontrib>Cohn, Susan L</creatorcontrib><creatorcontrib>Maris, John M</creatorcontrib><creatorcontrib>London, Wendy B</creatorcontrib><creatorcontrib>Buxton, Allen</creatorcontrib><creatorcontrib>Stram, Daniel</creatorcontrib><creatorcontrib>Castleberry, Robert P</creatorcontrib><creatorcontrib>Shimada, Hiroyuki</creatorcontrib><creatorcontrib>Sandler, Anthony</creatorcontrib><creatorcontrib>Shamberger, Robert C</creatorcontrib><creatorcontrib>Look, A. Thomas</creatorcontrib><creatorcontrib>Reynolds, C. Patrick</creatorcontrib><creatorcontrib>Seeger, Robert C</creatorcontrib><creatorcontrib>Matthay, Katherine K</creatorcontrib><creatorcontrib>Children’s Oncology Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baker, David L</au><au>Schmidt, Mary L</au><au>Cohn, Susan L</au><au>Maris, John M</au><au>London, Wendy B</au><au>Buxton, Allen</au><au>Stram, Daniel</au><au>Castleberry, Robert P</au><au>Shimada, Hiroyuki</au><au>Sandler, Anthony</au><au>Shamberger, Robert C</au><au>Look, A. Thomas</au><au>Reynolds, C. Patrick</au><au>Seeger, Robert C</au><au>Matthay, Katherine K</au><aucorp>Children’s Oncology Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2010-09-30</date><risdate>2010</risdate><volume>363</volume><issue>14</issue><spage>1313</spage><epage>1323</epage><pages>1313-1323</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>The treatment of neuroblastoma has produced remarkable results with intensive combination chemotherapy. The authors attempted to reduce the duration of treatment in patients with intermediate-risk disease while maintaining a 3-year overall survival rate of more than 90%.
Neuroblastoma is the most common extracranial solid tumor in childhood, accounting for 50% of neoplasms diagnosed in the first year of life.
1
This disease has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending on the biologic features of the tumor.
2
–
6
Identification of risk groups on the basis of clinical and molecular prognostic variables has allowed tailoring of therapy to improve outcomes and minimize the risk of deleterious consequences of therapy.
7
–
14
In 1998, the Children's Oncology Group (COG) established a system of risk stratification for neuroblastoma that was based on clinical data (the patient's . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>20879880</pmid><doi>10.1056/NEJMoa1001527</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2010-09, Vol.363 (14), p.1313-1323 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_755967799 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Carboplatin - administration & dosage Chemotherapy Child Child, Preschool Children & youth Cyclophosphamide - administration & dosage Deoxyribonucleic acid DNA Doxorubicin - administration & dosage Etoposide - administration & dosage Humans Infant Intention to Treat Analysis Medical research Neoplasm Staging Neuroblastoma - drug therapy Neuroblastoma - mortality Neuroblastoma - pathology Prospective Studies Survival Analysis Treatment Outcome |
| title | Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A56%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20after%20Reduced%20Chemotherapy%20for%20Intermediate-Risk%20Neuroblastoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Baker,%20David%20L&rft.aucorp=Children%E2%80%99s%20Oncology%20Group&rft.date=2010-09-30&rft.volume=363&rft.issue=14&rft.spage=1313&rft.epage=1323&rft.pages=1313-1323&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1001527&rft_dat=%3Cproquest_pubme%3E2151593791%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755967799&rft_id=info:pmid/20879880&rfr_iscdi=true |